MX355885B - Composición farmacéutica de administración oral. - Google Patents

Composición farmacéutica de administración oral.

Info

Publication number
MX355885B
MX355885B MX2014009833A MX2014009833A MX355885B MX 355885 B MX355885 B MX 355885B MX 2014009833 A MX2014009833 A MX 2014009833A MX 2014009833 A MX2014009833 A MX 2014009833A MX 355885 B MX355885 B MX 355885B
Authority
MX
Mexico
Prior art keywords
pharmaceutical composition
oral pharmaceutical
iminopyrrolidine
trifluorothymidine
ftd
Prior art date
Application number
MX2014009833A
Other languages
English (en)
Other versions
MX2014009833A (es
Inventor
Yoshito Ohnishi
Original Assignee
Taiho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48984243&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX355885(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Taiho Pharmaceutical Co Ltd filed Critical Taiho Pharmaceutical Co Ltd
Publication of MX2014009833A publication Critical patent/MX2014009833A/es
Publication of MX355885B publication Critical patent/MX355885B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Biochemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La invención presente proporciona una composición farmacéutica oralmente administrable que contiene FTD y TPI que puede ser administrada oralmente y que es estable incluso bajo condiciones de alta humedad; una composición farmacéutica oralmente administrable que comprende a,a,a-trifluorotimidina y clorhidrato de 5-cloro-6-(2-iminopirrolidina-1-il)metil-2,4(1H,3H)-pirimidina diona como ingredientes activos y aditivos que tiene una humedad relativa crítica de 85% o más a 25°C como un excipiente.
MX2014009833A 2012-02-15 2013-02-14 Composición farmacéutica de administración oral. MX355885B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2012031143 2012-02-15
PCT/JP2013/053513 WO2013122134A1 (ja) 2012-02-15 2013-02-14 経口投与用医薬組成物

Publications (2)

Publication Number Publication Date
MX2014009833A MX2014009833A (es) 2014-09-11
MX355885B true MX355885B (es) 2018-05-02

Family

ID=48984243

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014009833A MX355885B (es) 2012-02-15 2013-02-14 Composición farmacéutica de administración oral.

Country Status (25)

Country Link
US (2) US20140356431A1 (es)
EP (1) EP2815753B1 (es)
JP (1) JP5798641B2 (es)
KR (2) KR20150001717A (es)
CN (1) CN104105491B (es)
AU (1) AU2013219382B2 (es)
BR (1) BR112014018273B1 (es)
CA (1) CA2861480C (es)
CY (1) CY1120530T1 (es)
DK (1) DK2815753T3 (es)
ES (1) ES2683825T3 (es)
HK (1) HK1199822A1 (es)
HR (1) HRP20181193T1 (es)
HU (1) HUE039487T2 (es)
LT (1) LT2815753T (es)
MX (1) MX355885B (es)
MY (1) MY155922A (es)
PL (1) PL2815753T3 (es)
PT (1) PT2815753T (es)
RS (1) RS57505B1 (es)
RU (1) RU2600831C2 (es)
SG (1) SG11201403874SA (es)
SI (1) SI2815753T1 (es)
TW (1) TWI503122B (es)
WO (1) WO2013122134A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106551946B (zh) * 2015-09-24 2020-02-14 江苏奥赛康药业有限公司 一种含三氟胸苷和盐酸替比嘧啶的药物组合物及制备方法
CN106913580A (zh) * 2015-12-27 2017-07-04 南京圣和药业股份有限公司 一种含曲氟尿苷盐酸替哌拉索的药物组合物及其应用
CN106018573B (zh) * 2016-03-16 2018-09-18 江苏悦兴药业有限公司 一种tas-102中盐酸替比拉西的纯度检测方法
CN105963271A (zh) * 2016-06-01 2016-09-28 国药心制药有限公司 一种药用辅料组合物及一种曲氟尿苷、盐酸替匹嘧啶薄膜衣片
EP3730935A4 (en) 2017-12-22 2022-02-23 Taiho Pharmaceutical Co., Ltd. METHOD OF DETECTING ANALOGUES OF TRIFLURIDIN AND/OR TIPIRACIL
US10866219B2 (en) 2017-12-22 2020-12-15 Taiho Pharmaceutical Co., Ltd. Method for detecting trifluridine- and/or tipiracil-related substance
US10816517B2 (en) * 2018-01-05 2020-10-27 Taiho Pharmaceutical Co., Ltd. Method for detecting trifluridine-related substance by high-performance liquid chromatography
WO2019135405A1 (ja) 2018-01-05 2019-07-11 大鵬薬品工業株式会社 トリフルリジン由来の類縁物質の検出方法
WO2019171394A1 (en) 2018-03-03 2019-09-12 Natco Pharma Limited Stable pharmaceutical compositions comprising trifluridine and tipiracil hydrochloride

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2203683T3 (es) * 1995-03-29 2004-04-16 Taiho Pharmaceutical Company Limited Derivados de uracilo, agentes de potencializacion de efecto antitumoral y agente antitumoral que incluye estos derivados.
JPH11322604A (ja) * 1998-05-06 1999-11-24 Pola Chem Ind Inc ジフェニルピペラジン化合物を含有する製剤
PT1179342E (pt) 1999-05-21 2006-07-31 Kissei Pharmaceutical Composicoes medicinais de libertacao imediata para utilizacao oral
JP4110347B2 (ja) * 1999-11-05 2008-07-02 大鵬薬品工業株式会社 抗ｈｉｖ剤
JP4601934B2 (ja) * 2003-10-06 2010-12-22 ナガセ医薬品株式会社 ユビデカレノン錠
JP2005314413A (ja) * 2004-04-02 2005-11-10 Ono Pharmaceut Co Ltd 経口投与用医薬組成物
PE20060484A1 (es) * 2004-07-14 2006-07-06 Ucb Farchim Sa Preparaciones farmaceuticas liquidas que comprenden un compuesto de benzhidril piperizina
HUE033306T2 (hu) 2005-01-26 2017-11-28 Taiho Pharmaceutical Co Ltd Alfa, alfa, alfa-trifluortimidint és timidin-foszforiláz inhibitort tartalmazó rákellenes drog
US7799783B2 (en) * 2005-01-26 2010-09-21 Taiho Pharmaceutical Co., Ltd. Method of administrating an anticancer drug containing α, α, α-trifluorothymidine and thymidine phosphorylase inhibitor
AU2007242332B2 (en) * 2006-04-13 2012-02-02 Taiho Pharmaceutical Co., Ltd. Therapeutic agent for inflammatory bowel disease
JP2007284390A (ja) * 2006-04-18 2007-11-01 Ohara Yakuhin Kogyo Kk 塩酸イミダプリル含有錠剤
RU2346684C2 (ru) * 2007-04-04 2009-02-20 Закрытое акционерное общество "Биологические исследования и системы" Фармацевтическая композиция на основе сигетина

Also Published As

Publication number Publication date
US20140356431A1 (en) 2014-12-04
AU2013219382B2 (en) 2016-05-05
MY155922A (en) 2015-12-16
HRP20181193T1 (hr) 2018-10-19
SG11201403874SA (en) 2014-10-30
RU2600831C2 (ru) 2016-10-27
WO2013122134A1 (ja) 2013-08-22
RU2014137096A (ru) 2016-04-10
HK1199822A1 (zh) 2015-07-24
TW201336498A (zh) 2013-09-16
CY1120530T1 (el) 2019-07-10
US20210220384A1 (en) 2021-07-22
KR20170029021A (ko) 2017-03-14
KR20150001717A (ko) 2015-01-06
EP2815753A4 (en) 2015-07-01
CA2861480C (en) 2019-02-12
BR112014018273B1 (pt) 2023-04-25
LT2815753T (lt) 2018-09-10
BR112014018273A2 (es) 2017-06-20
CN104105491B (zh) 2016-06-15
AU2013219382A1 (en) 2014-08-14
PT2815753T (pt) 2018-10-08
SI2815753T1 (sl) 2018-11-30
BR112014018273A8 (pt) 2021-09-28
JP5798641B2 (ja) 2015-10-21
PL2815753T3 (pl) 2018-10-31
MX2014009833A (es) 2014-09-11
DK2815753T3 (en) 2018-08-13
EP2815753B1 (en) 2018-05-16
CA2861480A1 (en) 2013-08-22
CN104105491A (zh) 2014-10-15
JPWO2013122134A1 (ja) 2015-05-18
KR101951575B1 (ko) 2019-02-22
EP2815753A1 (en) 2014-12-24
ES2683825T3 (es) 2018-09-28
TWI503122B (zh) 2015-10-11
RS57505B1 (sr) 2018-10-31
HUE039487T2 (hu) 2019-01-28

Similar Documents

Publication Publication Date Title
MX355885B (es) Composición farmacéutica de administración oral.
MX365313B (es) Composición farmacéutica oral que comprende a,a,a-trifluorotimidin a y clorhidrato de 5-cloro-6-(2-iminopirrolidina-1-il)metil-2,4(1h ,3h)-pirimidina diona.
AU2012259422A8 (en) Solid forms of a pharmaceutically active substance
WO2016131067A3 (en) Pharmaceutical compositions comprising meloxicam
PH12015501595A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
SG10201810985XA (en) Tofacitinib oral sustained release dosage forms
PH12015501598A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
WO2014205389A8 (en) Nuclear transport modulators and uses thereof
PH12015501600A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
EP3040072A4 (en) Pharmaceutical composition having pyrimidine compound as active ingredient
MY188450A (en) Spiro-lactam nmda receptor modulators and uses thereof
MX2010004576A (es) Derivados de pirimidina novedosos.
UA103332C2 (ru) Фармацевтическая композиция, которая содержит непептидный активный агент с первичной или вторичной аминогруппой
MY183312A (en) Pharmaceutical formulation
WO2014045162A8 (en) ALKYL-SUBSTITUTED HEXAHYDROPYRANO[3,4-d] [1,3]THIAZIN-2-AMINE COMPOUNDS
PH12018501072A1 (en) Modified release orally administered amino acid formulations
MY173573A (en) Pyridin-4-yl derivatives
WO2013003827A3 (en) Macrogol 15 hydroxystearate formulations
MY168212A (en) A new therapeutical composition containing apomorphine as active ingredient
WO2013106068A3 (en) Therapeutic compositions of specified herbal formulations and uses thereof
NZ711754A (en) Pharmaceutical compositions for the treatment of helicobacter pylori
MX2018006005A (es) Formulaciones que comprenden sales de oxalato de teneligliptin y solvatos de este.
WO2015002755A3 (en) Compounds for the treatment of malaria
MX2015012153A (es) Inhibidores de la quinasa pirrolopirimidina cdk9.
EA032913B1 (ru) Препараты производных пиримидиндиона

Legal Events

Date Code Title Description
FG Grant or registration